Drug Trial Radar · NCT03873987
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
Last checked: Nov 19, 2026Latest source record: Apr 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Jul 16, 2019
Primary completion
Aug 27, 2019
Study completion Sep 4, 2019
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin
Conditions
- Acute Bacterial Skin and Skin Structure Infection
Interventions
Current Formulation of OritavancinDrug
Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
KimyrsaDrug
New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Exposure of AUC of the New Formulation to the Approved FormulationTime frame: 72 hours
- Relative Exposure of AUC of the New Formulation to the Approved FormulationTime frame: 168 hours (Day 8)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
ML-ORI-102 Study Site
Chula Vista, California
ML-ORI-102 Study Site
La Mesa, California
ML-ORI-102 Study Site
Burr Ridge, Illinois
ML-ORI-102 Study Site
Somers Point, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.